Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.
James Waldron
Oct 24, 2025 9:15am
Biogen discontinues all AAV gene therapy work
Sep 26, 2025 11:04am
Biogen inks $85M Alcyone buyout to acquire drug delivery tech
Sep 18, 2025 10:30am
Biogen to take Spinraza follow-up into registrational studies
Jun 25, 2025 8:04am
Biogen blueprints $1B CNS deal with RNAi biotech
May 27, 2025 10:55am
Biogen pays Stoke $165M, bagging Dravet drug to fire up pipeline
Feb 18, 2025 9:28am
